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All consecutive patients implanted with Bi-V or Tri-V pacing devices (with or without defibrillator) at
The Heart Hospital UCLH, from January 2005 to December 2008 were considered potentially eligible for this analysis.
In our Institution, patients were implanted with CRTs at the time if they had symptomatic heart failure (New York Heart Association class II to IV) despite maximally tolerated medical therapy, had left ventricular ejection fraction (LVEF) < 35%, and QRS duration ≥ 150ms (or QRS < 150ms with echocardiographic evidence of mechanical dyssynchrony). Patients were not considered for the purpose of this analysis if they were aged < 18, if they required intravenous inotropic drug therapy, or had an estimated life expectancy of < 12 months due to a cause other than heart failure. Patients with unsuccessful coronary sinus lead insertion during the procedure were also excluded to preserve homogeneity while comparing groups in this as-treated analysis.
Our Centre's initial experience with Tri-V pacing has been published previously [7] . In the initial study, during the first 12 months post-implant, Tri-V devices were randomly switched between four different pacing configurations: Tri-V; standard Bi-V; dual site left ventricular (LV) or right ventricular (RV) pacing; and single site RV or LV pacing; and then programmed with the configuration providing the best echocardiographic and clinical response [7] . Therefore, for the purpose of this as-treated analysis, Tri-V patients were considered eligible if they were programmed with all three ventricular leads on after the first 12 months (i.e. if they were receiving true Tri-V pacing). Similarly, patients in the control group had to be alive after the first year post-implant and should be receiving effective Bi-V pacing.
Propensity score matching with a 1:1 ratio was used to obtain a control group of standard CRT patients (Bi-V group) and assure that Tri-V and their contemporary Bi-V controls were similar in all baseline variables. Probabilities in the Tri-V group were matched 1:1 to the best Bi-V corresponding patient.
pacing. An LV lead was inserted into a lateral or posterolateral branch of the coronary sinus. Where possible, a further lead was implanted into another lateral or anterolateral branch of the CS, or into the middle cardiac vein, aiming for maximal orthogonal separation between the pacing sites of the three ventricular leads. No measurement of local ventricular electrogram delay or acute haemodynamics was made during the implantation.
The leads were attached to a standard CRT device (Contak Renewal 4, Boston Scientific, USA; Atlas-HF, St Jude Medical, USA). Choice of a CRT-P or CRT-D was based in the patient's clinical history, risk profile, and past arrhythmic events. In patients with permanent AF, the third ventricular lead was connected to the atrial port of the device and the AV delay programmed to the minimum allowed by the device (10ms). In those patients receiving an atrial lead, two ventricular leads were paired together using a twin bipolar-to-bipolar connector (Oscor, Palm Harbor, FL, USA). The paired leads were connected to the LV port and the unpaired final lead was connected to the RV port.
Device Programming
As this study occurred in the pre-MADIT-RIT era [8] , all devices were programmed with two ventricular tachycardia zones ab initium, based on patient's age and presence of previous ventricular arrhythmia events. Ventricular tachycardia (VT) zone was programmed starting at 169±11bpm in Bi-V vs. 171±9bpm in Tri-V (P=0.435) and ventricular fibrillation (VF) zone was programmed starting at 209±11bpm in Bi-V vs. 206±9bpm in Tri-V (P=0.199). Nominal number of intervals for initial detection was used and detection was set to 2.5s-9.0s (depending on manufacturer) in the VT zone and 1.0s-5.0s in the VF zone. Supraventricular tachycardia discriminators were switched on and highrate timeout turned off. Anti-tachycardia pacing (ATP) and shocks were programmed in the VT and VF zone. Subsequent adjustments to therapies and detection zones were performed during follow-up, or following the occurrence of any arrhythmic events.
Follow-up and Outcomes
Safety data and the presence of complications including lead dislodgement, lead failure (defined as lead performing inappropriately and requiring replacement), device-related infection (whether pocket or lead infection), phrenic nerve capture refractory to electronic programming (requiring temporarily switching off the LV lead and repositioning or insertion of a new lead), pneumothorax and haematoma requiring drainage or bleeding requiring red blood cell transfusion was recorded. Device longevity, measured as time to box change, was compared in the two groups.
Mortality data (all-cause mortality) and information on patients accepted for heart transplant were collected through hospital reports. In patients who transferred their follow-up to another hospital, long-term follow-up data was retrieved. When patients were lost to hospital follow-up, data was collected through patients' registered general practitioners.
Data from our local device clinic follow-up records and stored device electrograms (EGMs) during episodes of detected VT, VF, any therapy deliveries, and inappropriate shocks were analysed by a cardiac physiologist specialized in electrophysiogy and a Consultant Electrophysiologist or Senior Electrophysiology Fellow. Sustained ventricular tachycardia episodes meeting criteria for appropriate implantable cardioverter-defibrillator (ICD) intervention were classified as either VT/VF, according to the rate and detection window where therapy was delivered. Non sustained VT episodes which met detection criteria and terminated before therapy was delivered were not classified as VT/VF.
Patients were classified as having had appropriate shocks, if a shock was delivered during a VT or VF event. An effective ATP therapy was defined as overdrive ventricular pacing able to restore sinus rhythm following a VT or VF episode. An appropriate ICD intervention was classified as the presence of either an appropriate shock or an effective ATP.
The incidence of inappropriate shocks delivered due to misdetection of tachycardia (either supraventricular tachycardia, sinus tachycardia, fast AF or artefact) was also compared between the two treatment groups.
Data regarding multiple arrhythmia episodes (either in the VT or VF zones), and appropriate ICD therapies (ATPs and appropriate shocks) in a same patient were collected, and the mean number of was compared between the two groups. The presence of arrhythmic storm, defined as ≥ 3 sustained episodes of VT, VF, or appropriate ICD therapies during a 24-hour period, was also documented.
From 2011 onwards, home-monitoring systems (LATITUDE and MERLIN) became available in our Institution and were also used for follow-up purposes.
Statistical analysis
A propensity score was obtained for all participants undergoing a transvenous CRT implantation through binary logistic regression: CRT modality (Tri-V or Bi-V) was the binary outcome and all baseline variables (mentioned above) were used as covariates for estimating a probability (the propensity score). Then, probabilities in the Tri-V group were matched 1:1 to the closest Bi-V patient fulfilling inclusion criteria using the nearest neighbour matching approach. The propensity score was matched to 5 decimals whenever possible. If this was not possible, we subsequently attempted 4, 3 and then 2 decimal matching. If a treated subject could not be matched to any untreated subject on the second digit of the propensity score, then the treated subject was discarded from the matched analysis.
Histograms and comparison of means and medians, were used for assessing distribution and matching success.
Comparisons between Tri-V and Bi-V were performed. Based on Stuart [9] , analyses were performed using the groups as a whole, rather than using the individual matched pairs. Chi-square was used for the comparison of nominal variables. The student t-test, or its non-parametric equivalent, MannWhitney when appropriate, was used for comparison of continuous variables; the Levene's test was used in order to check the homogeneity of variance. Results with P < 0.05 were regarded as significant.
Kaplan-Meier curves were traced for comparing survival (freedom from all-cause mortality or heart transplant, and ventricular arrhythmia events or ICD therapies) among the two intervention groups.
Hazard ratio was used for assessing the existence of differences. For the endpoint of all-cause mortality or heart transplant, both an as-treated analysis (including 34 Tri-V patients treated with Tri-V pacing following the first 12 months) and an intention-to-treat analysis (including all 45 patients initially implanted with Tri-V devices) were performed. For the purpose of time to event analysis only time to first event was considered (Kaplan-Meier analysis and Cox Regression). For every specific assessed endpoint, the patients were censored after their first event.
Independent predictor endpoints for mortality, cardiac transplantation and appropriate ICD interventions were assessed through multivariate Cox regression. All variables were assessed for potential inclusion in the model, and were then selected using the forward likelihood ratio method, with a probability for stepwise of 0.05. PASW Statistics (SPSS Inc, Chicago, IL) version 18.0 was used for descriptive and inferential statistical analysis.
Results
During the pre-specified time interval 327 patients were implanted with CRT devices. Out of 45 patients implanted with TRI-V pacing devices during the pre-specified time window, 34 filled the inclusion criteria and were included in this analysis. Among the remaining 282 contemporary patients implanted with Bi-V devices, 34 controls were selected through propensity matching.
Reasons for Tri-V patients not being included in the as-treated analysis included: death in the first year post-implant and consequently before being programmed as Tri-V full-time (n=4), and programmed as dual LV-pacing only (no RV pacing; n=3) after 12 months, standard Bi-V pacing after Baseline variables of the study cohort comparison of Tri-V and Bi-V groups are shown in Table 1 .
Bi-V group, this was observed in 5 patients: 2 presented with RA lead displacement, 1 with CS lead displacement and two with both RV and CS lead displacement. One case happened in the first week, two more in the first 6 months and the remainder at a later date. No significant differences were observed in the incidence of this complication between the two groups (Tri-V 0.86 per 100 patientyears vs. Bi-V 1.10 per 100 patient-years; P=0.742) ( Table 3) .
Infection was reported in 7 patients (4 in the Tri-V group vs. 3 patients treated with BI-V devices). In all but two cases, infections occurred following more than one year after the initial device implant Among the 11 Tri-V patients not included in this as-treated analysis, observed issues were: one patient had a micro-dislodgement of the CS lead with loss of capture in the first year and was left with dual-RV pacing as she presented with very good haemodynamic and echo response (still alive 3,319 days after the implant procedure); a second patient had a CS lead dislodgement at 30 days requiring repositioning, complicated by infection and system extraction at 6 months. This patient was later implanted with a standard Bi-V device and died 2,244 days following the initial Tri-V implant; A third patient, with a Tri-V with 2 CS leads had phrenic nerve capture with one of the CS leads, reason why he had to be programmed as a standard CRT-D. This patient died 68 days following the initial Tri-V implantation procedure.
Arrhythmic Events

Long-term survival
During follow-up, 37 patients (16 Tri-V vs. 21 Bi-V recipients) died and 1 patient from the Bi-V group underwent heart transplant. The overall incidence of all-cause mortality or heart transplant was 9.17 per 100 patient-years (95%CI 6.75-12-33).
A trend for lower all-cause mortality and heart transplant was observed in the 
Discussion
We have observed a potential benefit of Tri-V pacing compared with standard Bi-V in long term survival, ventricular arrhythmia burden and need of ICD interventions. Also, the incidence of safetyrelated events or complications with Tri-V was comparable to standard BI-V devices, with a low incidence of lead failure, lead dislodgment and infections.
To the best of our knowledge this is the first study demonstrating an impact of Tri-V on long-term clinical outcomes. Previous studies have shown a potential improvement in patients heart failure symptoms (New York Heart Association class and quality of life Minnesota Living With Heart Failure Score [7, 10, 11] , peak oxygen consumption -VO2max [10], 6-minute walking distance [7, 10] ) and haemodynamic (increase in dP/dT and cardiac output [12] [13] [14] ) benefit, as well as echocardiographic evidence of reverse remodelling (improvement in LVEF [6, 7, 10] , LV dimensions [7] and intraventricular synchrony [10] ).
Bi-V pacing is thought to improve synchrony in patients with left bundle branch block by enhancing myocardial recruitment through simultaneous stimulation of the LV free wall and septum, thus reducing regional dispersions of delayed activation. However, both the haemodynamic response and progression of the depolarizing wave-front can be affected by the conduction properties of the myocardium [15] . The location and extent of myocardial scarring may also influence response to Bi-V, as scarred regions can prevent or delay progression of the activation wave-front and the synchronized engagement of viable tissue, or if scarring is extensive there may be inadequate volume of healthy myocardium recruited to improve haemodynamics [16, 17] . The potential advantage of Tri-V pacing and the mechanism underlying the observed clinical and echocardiographic benefit, may reside in the possibility of direct stimulation of wider regions of myocardial tissue simultaneously, or allowing the depolarization wave-front to bypass regions of slow conduction or scar and reaching previously delayed or remote sites more quickly [7] .
Ogano et al. have also suggested that Tri-V might affect repolarization indexes (corrected QT interval, and transmural dispersion of repolarization) and therefore exert anti-arrhythmic effects leading to a reduction of ventricular arrhythmia [18] . Other contributory factors can be LV reverse remodelling itself, as previously suggested in the MADIT-CRT study [19] , and reduction of 
Study limitations
We acknowledge several limitations in our work. First, the results of this single-centre study should be interpreted carefully in view of the small sample size and absence of randomization. The use of propensity-score matching provided an appropriately matched control group, attempting to minimize that issue. However, as small samples can sometimes lead to misleading results, our findings require validation in larger samples. Second, some patients with narrow QRS complex were implanted based on echocardiography dyssynchrony practice at the time, which was abandoned after the landmark studies PROSPECT [24] and EchoCRT [25] . However, groups were also matched for that type of currently off-label patients, and some are still alive at 10 years. Third, due to the exploratory nature of this long-term cohort follow-up, there was no baseline power assessment. However, it is striking that for some of the assessed endpoints this study was able to suggest a marked reduction and benefit in favor of Tri-V treated patients. Lastly, even though both groups were matched for baseline variables, device brands and had similar cutoffs for zone programming, we cannot entirely rule out that unaccounted aspects in detection or therapy programming can have contributed in part to the observed differences in ventricular arrhythmia events.
Conclusion
In this exploratory pilot single-centre study Tri-V presented promising results, and compared with Bi-V it displayed a similar safety profile and potential benefits as regards long-term survival and ventricular arrhythmia burden. These findings support the need of future long-term and sufficiently powered randomized controlled studies to assess the impact of this pacing modality on hard clinical outcomes like mortality and arrhythmic events.
Perspectives
Competency in Medical Knowledge: This exploratory study raises the possibility of a survival benefit from Tri-V pacing in patients with advanced Heart Failure. This may be of interest as almost a third of patients are non-responders to conventional CRT.
Competency in Patient Care:
These results suggest that CRT can still be improved and in the next decades we may expect better survival and outcomes in the advanced heart failure setting. However, a confirmatory randomized controlled trial confirming the positive performance of Tri-V pacing before it becomes routine practice or an alternative to Bi-V non-responders is warranted. Legend: HR -hazard ratio; CI -confidence interval.
